← All trials
NCT00633321
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2007
- Primary completion
- Dec 1, 2008
- Completion date
- Feb 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 522
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Celtic Pharma Development ServicesLead sponsor
- Mayo ClinicOverall official - principal investigator
- Benchmark ResearchOverall official - principal investigator
- Centennial Medical GroupOverall official - principal investigator
- CRI WorldwideOverall official - principal investigator
- CNS Research, Inc.Overall official - principal investigator
- Columbia UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.